TAOX

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-521.5K ExitQ1 2026 $522k -- $3.46
Jim SimonsRenaissance Technologies $579k101.8k shares AddQ1 2026 $316k $5.69 $3.46
Jim SimonsRenaissance Technologies $-228.4K TrimQ4 2025 $228k -- $3.46
Jim SimonsRenaissance Technologies $326.7K AddQ3 2025 $327k -- $3.46
Ken GriffinCitadel Advisors $-37.1K ExitQ2 2025 $37k -- $3.46

News

prnewswire.comTAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AIprnewswire.comJun 16

Trade TAOX

About TAO Synergies Inc.

TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.

CEO: Joshua N. Silverman
IPO Date: Jul 2, 2025

Market Data

Open: $3.89
High: $3.95
Low: $3.62
Volume: 120.7K
Avg Volume: 175.6K
52W High: $11.98
52W Low: $3.25

Valuation

Market Cap: $12.1M
Enterprise Value: $8.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$6.4M
Revenue: $299.1K
Net Income: -$28.7M
Cash: $5.5M
Debt: $0

Events

EarningsAug 7

EPS est. -12.75